HMHA1 anticorps

N° du produit ABIN7115031

Cet anticorps anti-HMHA1 est un anticorps Lapin Polyclonal détectant HMHA1 dans WB, ELISA et IHC. Adapté pour Humain, Rat et Souris.

Aperçu rapide pour HMHA1 anticorps (ABIN7115031)

Antigène: HMHA1 (Histocompatibility (Minor) HA-1 (HMHA1))

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HMHA1 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Détail du produit anti-HMHA1 anticorps

Fonction: ARHGAP45 antibody

Purification: Immunogen affinity purified

Pureté: ≥95 % as determined by SDS-PAGE

Immunogène: histocompatibility(minor) HA-1

Isotype: IgG

Information d'application

Indications d'application: WB: 1:500-1:2000, IHC: 1:20-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze / thaw cycles.

Stock: -20 °C

Stockage commentaire: -20°C for 12 months

Date de péremption: 12 months

Détails sur HMHA1

Antigène: HMHA1 (Histocompatibility (Minor) HA-1 (HMHA1))

Autre désignation: ARHGAP45

Sujet:

Synonyms: Rho GTPase-activating protein 45|Minor histocompatibility antigen HA-1 (mHag HA-1)|ARHGAP45|HMHA1|KIAA0223

Background: GTPase activator for the Rho-type GTPases. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens(mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease(GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation(BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte(CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Poids moléculaire: 140-150 kDa

ID gène: 23526

UniProt: Q92619